Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
BioDrugs is Scopus-indexed (Q1, CiteScore 13.8), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Adis.
Checked against the index lists dated .
ISSN 1173-8804Verify ISSN ↗1179-190XVerify ISSN ↗
Publisher: Adis
Cost to publish: About US$5,190 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 10 / 278 | 96th | Q1 |
| Pharmacology | 17 / 328 | 94th | Q1 |
| Biotechnology | 30 / 325 | 90th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1997–present, best quartile Q1, CiteScore 13.8.
BioDrugs is Q1 in Pharmacology (medical) (rank 10 of 278), Q1 in Pharmacology (rank 17 of 328) and Q1 in Biotechnology (rank 30 of 325), by CiteScore 2025.
BioDrugs is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 13.8, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.628, quartile Q1, with an H-index of 90.
The publisher lists an article processing charge of about US$5,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
BioDrugs is published by Adis. Its print ISSN is 1173-8804 and its online ISSN is 1179-190X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
BioDrugs has an h-index of 101 and a 2-year mean of 7.67 citations per paper (OpenAlex). Its Scopus CiteScore is 13.8, quartile Q1. On 2-year citations it ranks #10 of 271 Scopus journals in Pharmacology (medical).
BioDrugs published 61 papers in 2025; its busiest recent year was 2019 with 71. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2025–2026), authors are most often from United States (16.5%), China (14.4%) and South Korea (8.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.